Sophia Delicou, n/a

Head of Thalassemia and Sickle Cell Disease Unit,Head of the Expertise Center of Hemoglobinopathies
Hippokrateio General Hospital Athens
Rochester, Attiki, Greece

Presentation(s):

• Etavopivat Reduces Incidence of Vaso-Occlusive Crises in Patients with Sickle Cell Disease: HIBISCUS Trial Phase 2 Results through 52 Weeks

  Saturday, June 7, 2025
  9:00 AM - 9:20 AM ET